Abstract：Objective To investigate the clinical application effect of Butylphthalide Soft Capsules combined with Edaravone in treatment of cerebral infarction. Methods A total of 100 patients with cerebral infarction who were treated in Anshan Tumor Hospital from April 2018 to June 2020 were selected as the research objects. According to the computer random assignment method, the patients were assigned and divided into the control group (50 patients) and the experimental group (50 patients). The control group was treated with Edaravone, and the experimental group was treated with Butylphthalide Soft Capsules combined with Edaravone. The clinical efficacy, total incidence of adverse reactions,Barthel index and quality of life of the two groups were compared after treatment. Results The total effective rate of treatment of the experimental group was higher than that of the control group, and the difference was statistically significant (P＜0.05). The Barthel index of the experimental group was higher than that of the control group, with statistical significance (P＜0.05). The total incidence of adverse reactions in the experimental group was lower than that in the control group, the difference was statistically significant (P＜0.05). The scores of psychological function, material function, social function and physical function in the experimental group were higher than those in the control group, and the differences were statistically significant (P＜0.05). Conclusion The clinical efficacy of Butylphthalide Soft Capsules combined with Edaravone in the treatment of cerebral infarction is significant, which can effectively improve the quality of life of patients and reduce their adverse reactions.
京公网安备 11010502046607号